Taking medicine is an effective way to cure and manage diseases, then there is this case.

Fact is, low doses of aspirin to stop the onset of heart diseases and even certain kinds of cancer has become a norm to a lot of people. A new study however reveals that there is a big downside to this, especially for women who are under the age of 65.

A low-dose aspirin regimen in women below the age 65 has been proven to slightly decrease the risk of strokes, heart attacks and colon cancer, a new study published in the journal Heart have learned that it can also significantly increase the risk of significant gastrointestinal bleeding.

Under 65? Then think twice before taking low-dose aspirin.

Referring to the use of low-dose aspirin to prevent a heart in attack repeat in some patients, Cardiologist Dr. John Erwin of Scott & White Memorial Hospital in Texas clarified that there’s a little more into what doctors call “primary prevention.”

“There’s no question that aspirin can be a lifesaver for people who’ve already had a heart attack,” admits Erwin.
The issue lies in the fact that the benefit of low-dose aspirin use outweighs the risks involved in taking it which include stomach bleeding, ulcers, or even sometimes bleeding into the brain.

Only people considered at “high risk” of a heart attack should consider taking aspirin as on ongoing regimen according to the American Heart Association.

“It’s been a huge conundrum for us over the years,” Erwin adds. “When it comes to primary prevention, there are relatively few patients who will get a big benefit. And there’s always the risk of harm.”

The published research also noted that low-dose aspirin for prevention “is ineffective or harmful in the majority of women with regard to the combined risk of CVD (cardiovascular disease,) cancer and major gastrointestinal bleeding.”

The benefits on the other hand outweighs its risks for women older than 65.

“I probably wouldn’t take aspirin unless I had a very high risk of either cardiovascular disease or colon cancer,” Nancy Cook of Brigham & Women’s Hospital in Boston and Harvard Medical School and part of the research team said.